Skip to main content
S 3498 117th Congress Senate Health Advisory bodies Cardiovascular and respiratory health Congressional oversight Department of Health and Human Services Drug safety, medical device, and laboratory regulation Drug therapy Emergency medical services and trauma care Executive agency funding and structure Government information and archives Health programs administration and funding Health promotion and preventive care Immunology and vaccination Infectious and parasitic diseases Licensing and registrations Medical research Medical tests and diagnostic methods Research administration and funding

FORWARD Act of 2022

Introduced: January 13, 2022 Introduced by: Kelly, Mark Democratic · Arizona See on congress.gov
Sign in to write a letter Sign in to watch
 Everywhere this bill has been 2 steps
Introduced
In committee
Reported out
Passed House
Passed Senate
To President
Became law
Jan 13, 2022
Read twice and referred to the Committee on Health, Education, Labor, and Pensions.
Jan 13, 2022
Introduced in Senate
 Plain-English summary Congressional Research Service

Finding Orphan-disease Remedies With Antifungal Research and Development Act of 2022 or the FORWARD Act of 2022

This bill establishes programs to support research on endemic fungal diseases and the development of antifungal drugs, with a particular focus on Valley Fever. Endemic fungal diseases are fungal infections that tend to occur in specific geographic areas and affect older adults and other at-risk populations.

Specifically, the bill establishes the Endemic Fungal Disease Working Group to review, coordinate, and make recommendations about the Department of Health and Human Services' efforts to address endemic fungal diseases. The working group is comprised of experts from both relevant federal agencies and the private sector.

In addition, the National Institutes of Health must continue its support for research on endemic fungal diseases.

Furthermore, the Food and Drug Administration must issue guidance for entities seeking approval for therapies, diagnostics, and vaccines to prevent and treat Valley Fever. Additionally, the bill provides for the use of priority reviews and other fast-track procedures to incentivize and expedite development and approval of these medical products.

The bill also requires the Biomedical Advanced Research and Development Authority to implement the Combating Antimicrobial Resistance Biopharmaceutical Accelerator Program to reduce and prevent antimicrobial resistance.

What's happening now January 13, 2022

Read twice and referred to the Committee on Health, Education, Labor, and Pensions.

 Committees of jurisdiction 1